{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:52:28Z","timestamp":1782229948438,"version":"3.54.5"},"reference-count":119,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004374","name":"Chongqing Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272864"],"award-info":[{"award-number":["82272864"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes &amp; Diseases"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.gendis.2025.101983","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T03:20:09Z","timestamp":1765423209000},"page":"101983","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Uncovering genes driving developmental stage progression in prostate cancer through spatial transcriptomics"],"prefix":"10.1016","volume":"13","author":[{"given":"Yongjun","family":"Quan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingdong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchen","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.gendis.2025.101983_bib1","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.gendis.2025.101983_bib2","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.humpath.2010.02.011","article-title":"Multifocal prostate cancer: biologic, prognostic, and therapeutic implications","volume":"41","author":"Andreoiu","year":"2010","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.gendis.2025.101983_bib3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","article-title":"Genomic and phenotypic heterogeneity in prostate cancer","volume":"18","author":"Haffner","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"5991","key":"10.1016\/j.gendis.2025.101983_bib4","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1126\/science.1189992","article-title":"Identification of a cell of origin for human prostate cancer","volume":"329","author":"Goldstein","year":"2010","journal-title":"Science"},{"issue":"7263","key":"10.1016\/j.gendis.2025.101983_bib5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature08361","article-title":"A luminal epithelial stem cell that is a cell of origin for prostate cancer","volume":"461","author":"Wang","year":"2009","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.gendis.2025.101983_bib6","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/ncb2697","article-title":"Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity","volume":"15","author":"Wang","year":"2013","journal-title":"Nat Cell Biol"},{"issue":"6","key":"10.1016\/j.gendis.2025.101983_bib7","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0913873107","article-title":"Basal epithelial stem cells are efficient targets for prostate cancer initiation","volume":"107","author":"Lawson","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.gendis.2025.101983_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ceb.2015.10.002","article-title":"Cell types of origin for prostate cancer","volume":"37","author":"Lee","year":"2015","journal-title":"Curr Opin Cell Biol"},{"issue":"32","key":"10.1016\/j.gendis.2025.101983_bib9","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1038\/onc.2012.541","article-title":"Cells of origin for cancer: an updated view from prostate cancer","volume":"32","author":"Xin","year":"2013","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.gendis.2025.101983_bib10","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/stem.1094","article-title":"Human epithelial basal cells are cells of origin of prostate cancer, independent of CD133 status","volume":"30","author":"Taylor","year":"2012","journal-title":"Stem Cell"},{"issue":"1","key":"10.1016\/j.gendis.2025.101983_bib11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/pros.20111","article-title":"Characterization of prostatic neuroendocrine cell line established from neuroendocrine carcinoma of transgenic mouse allograft model","volume":"62","author":"Uchida","year":"2005","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.gendis.2025.101983_bib12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/gcc.21944","article-title":"High-resolution genome-wide copy-number analysis suggests a monoclonal origin of multifocal prostate cancer","volume":"51","author":"Boyd","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"issue":"7547","key":"10.1016\/j.gendis.2025.101983_bib13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.gendis.2025.101983_bib14","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nm.1944","article-title":"Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer","volume":"15","author":"Liu","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.gendis.2025.101983_bib15","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1038\/ncomms7605","article-title":"Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer","volume":"6","author":"Hong","year":"2015","journal-title":"Nat Commun"},{"issue":"7922","key":"10.1016\/j.gendis.2025.101983_bib16","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-022-05023-2","article-title":"Spatially resolved clonal copy number alterations in benign and malignant tissue","volume":"608","author":"Erickson","year":"2022","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.gendis.2025.101983_bib17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.eururo.2012.03.050","article-title":"Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins","volume":"63","author":"Lindberg","year":"2013","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.gendis.2025.101983_bib18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/jnci\/90.3.233","article-title":"Evidence of independent origin of multiple tumors from patients with prostate cancer","volume":"90","author":"Cheng","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.gendis.2025.101983_bib19","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1002\/(SICI)1097-0142(19981101)83:9<1995::AID-CNCR16>3.0.CO;2-2","article-title":"Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma","volume":"83","author":"Bostwick","year":"1998","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.gendis.2025.101983_bib20","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1002\/pros.20832","article-title":"Molecular analysis of multifocal prostate cancer by comparative genomic hybridization","volume":"68","author":"Kobayashi","year":"2008","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.gendis.2025.101983_bib21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41556-020-00613-6","article-title":"Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression","volume":"23","author":"Chen","year":"2021","journal-title":"Nat Cell Biol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101983_bib22","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s42003-020-01476-1","article-title":"Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer","volume":"3","author":"Dong","year":"2020","journal-title":"Commun Biol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101983_bib23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12943-020-01264-9","article-title":"Identification of a distinct luminal subgroup diagnosing and stratifying early stage prostate cancer by tissue-based single-cell RNA sequencing","volume":"19","author":"Ma","year":"2020","journal-title":"Mol Cancer"},{"issue":"5","key":"10.1016\/j.gendis.2025.101983_bib24","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nbt.3192","article-title":"Spatial reconstruction of single-cell gene expression data","volume":"33","author":"Satija","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.gendis.2025.101983_bib25","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nbt.3209","article-title":"High-throughput spatial mapping of single-cell RNA-seq data to tissue of origin","volume":"33","author":"Achim","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101983_bib26","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1038\/s41467-018-04724-5","article-title":"Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity","volume":"9","author":"Berglund","year":"2018","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.gendis.2025.101983_bib27","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.3390\/ijms24108955","article-title":"Spatial gene expression analysis reveals characteristic gene expression patterns of de novo neuroendocrine prostate cancer coexisting with androgen receptor pathway prostate cancer","volume":"24","author":"Watanabe","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6294","key":"10.1016\/j.gendis.2025.101983_bib28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aaf2403","article-title":"Visualization and analysis of gene expression in tissue sections by spatial transcriptomics","volume":"353","author":"St\u00e5hl","year":"2016","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.gendis.2025.101983_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108429","article-title":"Visium spatial transcriptomics reveals intratumor heterogeneity and profiles of gleason score progression in prostate cancer","volume":"26","author":"Quan","year":"2023","journal-title":"iScience"},{"issue":"9","key":"10.1016\/j.gendis.2025.101983_bib30","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.3390\/ijms25094818","article-title":"Unveiling the genomic landscape of intraductal carcinoma of the prostate using spatial gene expression analysis","volume":"25","author":"Watanabe","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.gendis.2025.101983_bib31","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1016\/j.csbj.2024.08.026","article-title":"UQCRB and LBH are correlated with gleason score progression in prostate cancer: spatial transcriptomics and experimental validation","volume":"23","author":"Quan","year":"2024","journal-title":"Comput Struct Biotechnol J"},{"issue":"12","key":"10.1016\/j.gendis.2025.101983_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111351","article-title":"Spatial transcriptomics identifies RBM39 as a gene associated with gleason score progression in prostate cancer","volume":"27","author":"Quan","year":"2024","journal-title":"iScience"},{"issue":"14","key":"10.1016\/j.gendis.2025.101983_bib33","doi-asserted-by":"crossref","first-page":"eadm7098","DOI":"10.1126\/sciadv.adm7098","article-title":"Identification of an anaplastic subtype of prostate cancer amenable to therapies targeting SP1 or translation elongation","volume":"10","author":"Zou","year":"2024","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.gendis.2025.101983_bib34","doi-asserted-by":"crossref","first-page":"9949","DOI":"10.1038\/s41467-024-54364-1","article-title":"Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer","volume":"15","author":"Kiviaho","year":"2024","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.gendis.2025.101983_bib35","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/s41588-025-02139-9","article-title":"Spatially resolved transcriptomic analysis of the adult human prostate","volume":"57","author":"Hu","year":"2025","journal-title":"Nat Genet"},{"issue":"13","key":"10.1016\/j.gendis.2025.101983_bib36","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1158\/0008-5472.CAN-25-0269","article-title":"Combining spatial transcriptomics, pseudotime, and machine learning enables discovery of biomarkers for prostate cancer","volume":"85","author":"Smelik","year":"2025","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.gendis.2025.101983_bib37","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.eururo.2006.07.051","article-title":"Should we replace the gleason score with the amount of high-grade prostate cancer?","volume":"51","author":"Vis","year":"2007","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.gendis.2025.101983_bib38","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0046-8177(92)90108-F","article-title":"Histologic grading of prostate cancer: a perspective","volume":"23","author":"Gleason","year":"1992","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.gendis.2025.101983_bib39","first-page":"125","article-title":"Classification of prostatic carcinomas","volume":"50","author":"Gleason","year":"1966","journal-title":"Cancer Chemother Rep"},{"issue":"2","key":"10.1016\/j.gendis.2025.101983_bib40","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101983_bib41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0022-5347(17)59889-4","article-title":"Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging","volume":"111","author":"Gleason","year":"1974","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.gendis.2025.101983_bib42","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0022-5347(05)00734-2","article-title":"How well does the gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden","volume":"175","author":"Andr\u00e9n","year":"2006","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.gendis.2025.101983_bib43","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/modpathol.3800054","article-title":"Gleason grading and prognostic factors in carcinoma of the prostate","volume":"17","author":"Humphrey","year":"2004","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.gendis.2025.101983_bib44","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nrurol.2010.9","article-title":"Clinical implications of changing definitions within the gleason grading system","volume":"7","author":"Lotan","year":"2010","journal-title":"Nat Rev Urol"},{"issue":"3","key":"10.1016\/j.gendis.2025.101983_bib45","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2012.10.002","article-title":"Natural history of early, localized prostate cancer: a final report from three decades of follow-up","volume":"63","author":"Popiolek","year":"2013","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.gendis.2025.101983_bib46","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1046\/j.1464-410X.2002.02669.x","article-title":"Prognostic value of the gleason score in prostate cancer","volume":"89","author":"Egevad","year":"2002","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.gendis.2025.101983_bib47","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.juro.2010.10.057","article-title":"Predicting 15-year prostate cancer specific mortality after radical prostatectomy","volume":"185","author":"Eggener","year":"2011","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.gendis.2025.101983_bib48","doi-asserted-by":"crossref","first-page":"415.e1","DOI":"10.1016\/j.urolonc.2016.03.019","article-title":"Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy","volume":"34","author":"Kozminski","year":"2016","journal-title":"Urol Oncol"},{"issue":"29","key":"10.1016\/j.gendis.2025.101983_bib49","doi-asserted-by":"crossref","first-page":"12054","DOI":"10.1073\/pnas.1104009108","article-title":"Advancing a clinically relevant perspective of the clonal nature of cancer","volume":"108","author":"Ruiz","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.gendis.2025.101983_bib50","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.gendis.2025.101983_bib51","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/PAS.0b013e3182556dcd","article-title":"Do adenocarcinomas of the prostate with gleason score (GS) \u22646 have the potential to metastasize to lymph nodes?","volume":"36","author":"Ross","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101983_bib52","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.urology.2013.03.054","article-title":"Gleason 6 prostate tumors diagnosed in the PSA era do not demonstrate the capacity for metastatic spread at the time of radical prostatectomy","volume":"82","author":"Donin","year":"2013","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.gendis.2025.101983_bib53","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/bju.12879","article-title":"Disease-specific death and metastasis do not occur in patients with gleason score \u22646 at radical prostatectomy","volume":"116","author":"Kweldam","year":"2015","journal-title":"BJU Int"},{"issue":"27","key":"10.1016\/j.gendis.2025.101983_bib54","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.22.00123","article-title":"Low-grade prostate cancer: time to stop calling it cancer","volume":"40","author":"Eggener","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101983_bib55","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00345-020-03583-4","article-title":"Should grade group 1 (GG1) be called cancer?","volume":"40","author":"Labbate","year":"2022","journal-title":"World J Urol"},{"issue":"10","key":"10.1016\/j.gendis.2025.101983_bib56","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nmeth.3971","article-title":"Diffusion pseudotime robustly reconstructs lineage branching","volume":"13","author":"Haghverdi","year":"2016","journal-title":"Nat Methods"},{"issue":"1","key":"10.1016\/j.gendis.2025.101983_bib57","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13059-017-1382-0","article-title":"SCANPY large-scale single-cell gene expression data analysis","volume":"19","author":"Wolf","year":"2018","journal-title":"Genome Biol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101983_bib58","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13059-019-1663-x","article-title":"PAGA: graph abstraction reconciles clustering with trajectory inference through a topology preserving map of single cells","volume":"20","author":"Wolf","year":"2019","journal-title":"Genome Biol"},{"issue":"2","key":"10.1016\/j.gendis.2025.101983_bib59","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","article-title":"An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics","volume":"173","author":"Liu","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.gendis.2025.101983_bib60","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12935-021-02438-1","article-title":"Construction of a risk prediction model using m6A RNA methylation regulators in prostate cancer: comprehensive bioinformatic analysis and histological validation","volume":"22","author":"Quan","year":"2022","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.gendis.2025.101983_bib61","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13027-016-0065-x","article-title":"p53 expression but not p16(INK4A) correlates with human papillomavirus-associated esophageal squamous cell carcinoma in Kazakh population","volume":"11","author":"Wang","year":"2016","journal-title":"Infect Agent Cancer"},{"issue":"12","key":"10.1016\/j.gendis.2025.101983_bib62","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1038\/s41388-018-0476-9","article-title":"Unbalanced YAP-SOX9 circuit drives stemness and malignant progression in esophageal squamous cell carcinoma","volume":"38","author":"Wang","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.gendis.2025.101983_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.981226","article-title":"Histone lysine methylation patterns in prostate cancer microenvironment infiltration: integrated bioinformatic analysis and histological validation","volume":"12","author":"Quan","year":"2022","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.gendis.2025.101983_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0137-7","article-title":"Overexpression of TFF3 is involved in prostate carcinogenesis via blocking mitochondria-mediated apoptosis","volume":"50","author":"Liu","year":"2018","journal-title":"Exp Mol Med"},{"issue":"3","key":"10.1016\/j.gendis.2025.101983_bib65","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/pros.20096","article-title":"Trefoil factor 3 is overexpressed in human prostate cancer","volume":"61","author":"Garraway","year":"2004","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.gendis.2025.101983_bib66","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/pros.20095","article-title":"Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays","volume":"61","author":"Faith","year":"2004","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.gendis.2025.101983_bib67","doi-asserted-by":"crossref","first-page":"41","DOI":"10.47162\/RJME.62.1.04","article-title":"HOXB13 and TFF3 can contribute to the prognostic stratification of prostate adenocarcinoma","volume":"62","author":"Timofte","year":"2021","journal-title":"Rom J Morphol Embryol"},{"issue":"4","key":"10.1016\/j.gendis.2025.101983_bib68","first-page":"605","article-title":"Analysis of laser-microdissected prostate cancer tissues reveals potential tumor markers","volume":"28","author":"Adler","year":"2011","journal-title":"Int J Mol Med"},{"issue":"8","key":"10.1016\/j.gendis.2025.101983_bib69","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/ijc.25209","article-title":"Promoter hypomethylation and upregulation of trefoil factors in prostate cancer","volume":"127","author":"Vestergaard","year":"2010","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.gendis.2025.101983_bib70","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.3390\/ijms18092017","article-title":"Comprehensive evaluation of TFF3 promoter hypomethylation and molecular biomarker potential for prostate cancer diagnosis and prognosis","volume":"18","author":"N\u00f8rgaard","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"4260","key":"10.1016\/j.gendis.2025.101983_bib71","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1126\/science.959840","article-title":"The clonal evolution of tumor cell populations","volume":"194","author":"Nowell","year":"1976","journal-title":"Science"},{"issue":"7381","key":"10.1016\/j.gendis.2025.101983_bib72","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.gendis.2025.101983_bib73","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.gendis.2025.101983_bib74","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1002\/cncr.20243","article-title":"Heterogeneity of gleason grade in multifocal adenocarcinoma of the prostate","volume":"100","author":"Arora","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.gendis.2025.101983_bib75","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.gendis.2025.101983_bib76","first-page":"6357","article-title":"Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer","volume":"9","author":"Ross","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.gendis.2025.101983_bib77","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0090-4295(98)00278-7","article-title":"Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases","volume":"52","author":"Sweat","year":"1998","journal-title":"Urology"},{"issue":"10231","key":"10.1016\/j.gendis.2025.101983_bib78","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.gendis.2025.101983_bib79","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101983_bib80","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with 18F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J Urol"},{"issue":"13","key":"10.1016\/j.gendis.2025.101983_bib81","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1001\/jama.287.13.1662","article-title":"Alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer","volume":"287","author":"Rubin","year":"2002","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.gendis.2025.101983_bib82","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1097\/PAS.0000000000000238","article-title":"Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference","volume":"38","author":"Epstein","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"10.1016\/j.gendis.2025.101983_bib83","doi-asserted-by":"crossref","first-page":"12287","DOI":"10.1007\/s13277-016-5075-1","article-title":"High alpha-methylacyl-coa racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer","volume":"37","author":"Box","year":"2016","journal-title":"Tumor Biol"},{"issue":"3","key":"10.1016\/j.gendis.2025.101983_bib84","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2018.10.053","article-title":"Results of prostate cancer screening in a unique cohort at 19yr of follow-up","volume":"75","author":"Osses","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101983_bib85","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European randomized study of screening for prostate cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101983_bib86","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/21681805.2017.1411392","article-title":"Eighteen-year follow-up of the g\u00f6teborg randomized population-based prostate cancer screening trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality","volume":"52","author":"Hugosson","year":"2018","journal-title":"Scand J Urol"},{"issue":"2","key":"10.1016\/j.gendis.2025.101983_bib87","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22693","article-title":"Ultrasensitive prostate-specific antigen level as a predictor of biochemical progression after robot-assisted radical prostatectomy: towards risk adapted follow-up","volume":"33","author":"Grivas","year":"2019","journal-title":"J Clin Lab Anal"},{"issue":"4","key":"10.1016\/j.gendis.2025.101983_bib88","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.gendis.2025.101983_bib89","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/ijc.20635","article-title":"Increased expression of prostate-specific G-protein-coupled receptor in human prostate intraepithelial neoplasia and prostate cancers","volume":"113","author":"Weng","year":"2005","journal-title":"Int J Cancer"},{"issue":"41","key":"10.1016\/j.gendis.2025.101983_bib90","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1038\/sj.onc.1204803","article-title":"Identification of a prostate-specific G-protein coupled receptor in prostate cancer","volume":"20","author":"Xia","year":"2001","journal-title":"Oncogene"},{"issue":"23","key":"10.1016\/j.gendis.2025.101983_bib91","first-page":"6568","article-title":"PSGR a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer","volume":"60","author":"Xu","year":"2000","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2025.101983_bib92","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/sj.pcan.4500836","article-title":"Quantitative expression profile of PSGR in prostate cancer","volume":"9","author":"Xu","year":"2006","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"8","key":"10.1016\/j.gendis.2025.101983_bib93","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/pros.20389","article-title":"The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-coa racemase","volume":"66","author":"Wang","year":"2006","journal-title":"Prostate"},{"issue":"16","key":"10.1016\/j.gendis.2025.101983_bib94","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/pros.21211","article-title":"PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine","volume":"70","author":"Rigau","year":"2010","journal-title":"Prostate"},{"issue":"8","key":"10.1016\/j.gendis.2025.101983_bib95","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2014.29","article-title":"PSGR promotes prostatic intraepithelial neoplasia and prostate cancer xenograft growth through NF-\u03baB","volume":"3","author":"Rodriguez","year":"2014","journal-title":"Oncogenesis"},{"issue":"9","key":"10.1016\/j.gendis.2025.101983_bib96","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/onc.2015.170","article-title":"Prostate-specific G-protein-coupled receptor collaborates with loss of PTEN to promote prostate cancer progression","volume":"35","author":"Rodriguez","year":"2016","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.gendis.2025.101983_bib97","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/jcb.20600","article-title":"Regulation of human prostate-specific G-protein coupled receptor, PSGR, by two distinct promoters and growth factors","volume":"96","author":"Weng","year":"2005","journal-title":"J Cell Biochem"},{"issue":"24","key":"10.1016\/j.gendis.2025.101983_bib98","doi-asserted-by":"crossref","first-page":"16218","DOI":"10.1074\/jbc.M109.012096","article-title":"Activation of an olfactory receptor inhibits proliferation of prostate cancer cells","volume":"284","author":"Neuhaus","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.gendis.2025.101983_bib99","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.canlet.2019.03.044","article-title":"Activation of PSGR with \u03b2-ionone suppresses prostate cancer progression by blocking androgen receptor nuclear translocation","volume":"453","author":"Xie","year":"2019","journal-title":"Cancer Lett"},{"issue":"13","key":"10.1016\/j.gendis.2025.101983_bib100","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.7150\/ijbs.63300","article-title":"The role of N-cadherin\/c-Jun\/NDRG1 axis in the progression of prostate cancer","volume":"17","author":"Quan","year":"2021","journal-title":"Int J Biol Sci"},{"issue":"2","key":"10.1016\/j.gendis.2025.101983_bib101","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/path.1605","article-title":"The role of c-Jun and c-Fos expression in androgen-independent prostate cancer","volume":"204","author":"Edwards","year":"2004","journal-title":"J Pathol"},{"issue":"7","key":"10.1016\/j.gendis.2025.101983_bib102","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1158\/0008-5472.CAN-07-6055","article-title":"Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer","volume":"68","author":"Ouyang","year":"2008","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2025.101983_bib103","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1038\/s41467-024-49234-9","article-title":"FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.gendis.2025.101983_bib104","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.bbamcr.2005.04.009","article-title":"Vasoactive intestinal peptide (VIP) induces c-fos expression in LNCaP prostate cancer cells through a mechanism that involves Ca2+ signalling. Implications in angiogenesis and neuroendocrine differentiation","volume":"1744","author":"Collado","year":"2005","journal-title":"Biochim Biophys Acta"},{"issue":"13","key":"10.1016\/j.gendis.2025.101983_bib105","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1038\/s41388-021-01724-6","article-title":"In vivo CRISPR inactivation of fos promotes prostate cancer progression by altering the associated AP-1 subunit Jun","volume":"40","author":"Riedel","year":"2021","journal-title":"Oncogene"},{"issue":"19","key":"10.1016\/j.gendis.2025.101983_bib106","doi-asserted-by":"crossref","first-page":"9425","DOI":"10.1158\/0008-5472.CAN-07-1310","article-title":"C-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells","volume":"67","author":"Zhang","year":"2007","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.gendis.2025.101983_bib107","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0022-5347(01)66361-4","article-title":"Increased expression of early growth response-1 messenger ribonucleic acid in prostatic adenocarcinoma","volume":"155","author":"Thigpen","year":"1996","journal-title":"J Urol"},{"issue":"11","key":"10.1016\/j.gendis.2025.101983_bib108","first-page":"2461","article-title":"Expression of early growth response genes in human prostate cancer","volume":"58","author":"Eid","year":"1998","journal-title":"Cancer Res"},{"issue":"27","key":"10.1016\/j.gendis.2025.101983_bib109","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1038\/sj.onc.1206560","article-title":"Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo","volume":"22","author":"Baron","year":"2003","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.gendis.2025.101983_bib110","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/jcb.20736","article-title":"Enhanced EGR1 activity promotes the growth of prostate cancer cells in an androgen-depleted environment","volume":"97","author":"Yang","year":"2006","journal-title":"J Cell Biochem"},{"issue":"2","key":"10.1016\/j.gendis.2025.101983_bib111","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.canlet.2011.11.021","article-title":"Induction of IGF-1R expression by EGR-1 facilitates the growth of prostate cancer cells","volume":"317","author":"Ma","year":"2012","journal-title":"Cancer Lett"},{"issue":"35","key":"10.1016\/j.gendis.2025.101983_bib112","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1038\/s41388-019-0873-8","article-title":"EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis","volume":"38","author":"Li","year":"2019","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.gendis.2025.101983_bib113","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s00432-019-02933-z","article-title":"Combined loss of TFF3 and PTEN is associated with lethal outcome and overall survival in men with prostate cancer","volume":"145","author":"Abou-Ouf","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101983_bib114","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3390\/medicina60010174","article-title":"PTEN, ERG, SPINK1, and TFF3 status and relationship in a prostate cancer cohort from Jordanian Arab population","volume":"60","author":"Al Bashir","year":"2024","journal-title":"Medicina (Kaunas)"},{"issue":"11","key":"10.1016\/j.gendis.2025.101983_bib115","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3390\/genes12111665","article-title":"Histone variant H2A.J is enriched in luminal epithelial gland cells","volume":"12","author":"Redon","year":"2021","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.gendis.2025.101983_bib116","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12935-022-02546-6","article-title":"SLC4A4 promotes prostate cancer progression in vivo and in vitro via AKT-mediated signalling pathway","volume":"22","author":"Liu","year":"2022","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.gendis.2025.101983_bib117","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0885328220975249","article-title":"The targeted inhibition of prostate cancer by iron-based nanoparticles based on bioinformatics","volume":"36","author":"Xiao","year":"2021","journal-title":"J Biomater Appl"},{"issue":"1","key":"10.1016\/j.gendis.2025.101983_bib118","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-72408-w","article-title":"Dissecting the novel molecular interactions of solute carrier family 4 member 4 (SLC4A4) for prostate cancer (PCa) progression","volume":"14","author":"Rashid","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.gendis.2025.101983_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217070","article-title":"SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer","volume":"597","author":"Chen","year":"2024","journal-title":"Cancer Lett"}],"container-title":["Genes &amp; Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304225004726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304225004726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:46:11Z","timestamp":1782229571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304225004726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":119,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2352304225004726"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2025.101983","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uncovering genes driving developmental stage progression in prostate cancer through spatial transcriptomics","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2025.101983","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101983"}}